X4 Pharmaceuticals (XFOR) said Monday it is partnering with European specialty drug maker Norgine to commercialize mavorixafor in Europe, Australia, and New Zealand, pending regulatory approvals in those regions for the immunodeficiency treatment.

Under the terms of the license and supply agreement, X4 will receive 28.5 million euros ($29.1 million) in upfront payments from privately-held Norgine and up to 226 million euros in additional payments as the medication achieves selected regulatory and commercial milestones. The company also is eligible for escalating double-digit royalties of up to the mid-twenties on any future net sales in the licensed territories, it said.

The US Food and Drug Administration has approved mavorixafor to treat WHIM syndrome, a rare congenital immunodeficiency disorder in patients aged 12 years and older. X4 said it is expecting to soon file a similar application for marketing approval for the selective CXCR4 receptor antagonist with the European Medicines Agency.

The companies are also expecting to work together on future regulatory filings, although X4 will continue to be responsible for phase 3 testing for mavorixafor as a prospective treatment for chronic neutropenia, another immunodeficiency disorder.

XFOR shares were down 8% in recent morning trading.

Price: 0.52, Change: -0.05, Percent Change: -7.95